Molecular Targeting of Critical Domains of AHI-1 Oncoprotein in Chronic Myeloid Leukemia Stem Cells Resistant to Current Tyrosine Kinase Inhibitor Therapy

对当前酪氨酸激酶抑制剂治疗耐药的慢性粒细胞白血病干细胞中 AHI-1 癌蛋白关键结构域的分子靶向

• 批准号: 238855
• 负责人: Jiang Xiaoyan
• 金额: $ 46.39万
• 依托单位: BC Cancer, part of PHSA (Vancouver)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-09-01 至 2015-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=238855&lang=en
• 关键词: Ahi-1; Bcr-Abl; Chronic Myeloid Leukemia; Drug Resistance; Hematopoietic Stem Cells; Immunoprecipitation And Mass Spectrometry; Oncogene; Protein Biochemistry And Protein Crystallography; Signal Transduction; Small Molecule Inhibitors

Introduction of Imatinib medication has improved treatment of chronic myeloid leukemia (CML), but early relapses and resistant disease prevent many patients from being cured. The frequency of resistance to current Imatinib therapy is 15-20%, increasing to

伊马替尼药物的引入改善了慢性粒细胞白血病（CML）的治疗，但早期复发和耐药疾病阻止了许多患者被治愈。对当前伊马替尼治疗的耐药频率为15- 20%，增加至20%。